[Rapamycin and CCI-779].

@article{Alexandre1999RapamycinAC,
  title={[Rapamycin and CCI-779].},
  author={J{\'e}r{\^o}me Alexandre and Eric Raymond and J P Armand},
  journal={Bulletin du cancer},
  year={1999},
  volume={86 10},
  pages={808-11}
}
Rapamycin (sirolimus) is a macrolide, related to cyclosporine with immunosuppressive properties and antiproliferative activity in various human tumor cells lines and tumor xenograft models. The cytosolic kinase mTOR which controls the initiation of the translation of messenger RNA is the main known target of rapamycin. During clinical studies, rapamycin given by oral route as immunosuppressant did not show dose-limited toxicity and only asymptomatic thrombopenia and hyperlipemia were observed… CONTINUE READING

From This Paper

Topics from this paper.

Similar Papers

Loading similar papers…